A Reversal for Zimmer Biomet Holdings Inc Is Not Near. Professional Options Traders Are Bullish

 A Reversal for Zimmer Biomet Holdings Inc Is Not Near. Professional Options Traders Are Bullish

In today’s session Zimmer Biomet Holdings Inc (ZBH) registered an unusually high (1,076) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious ZBH increase. With 1,076 contracts traded and 394 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: ZBH161216C00100000 closed last at: $4.3 or 12.2% down. About 120,193 shares traded hands. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 7.89% since April 11, 2016 and is downtrending. It has underperformed by 14.03% the S&P500.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Out of 16 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 12 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 75% are positive. $155 is the highest target while $105 is the lowest. The $130.57 average target is 30.41% above today’s ($100.12) stock price. Zimmer Biomet Holdings has been the topic of 24 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Suntrust Robinson initiated it with “Buy” rating and $155 target price in Thursday, August 11 report. The firm has “Buy” rating given on Wednesday, May 25 by Argus Research. The firm earned “Neutral” rating on Tuesday, November 8 by Northcoast. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has “Buy” rating given on Friday, January 29 by Needham. As per Friday, September 4, the company rating was maintained by Canaccord Genuity. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has “Buy” rating given on Wednesday, November 4 by Sterne Agee CRT. As per Tuesday, September 22, the company rating was initiated by UBS. UBS maintained Zimmer Biomet Holdings Inc (NYSE:ZBH) rating on Tuesday, August 2. UBS has “Neutral” rating and $132 price target. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) earned “Outperform” rating by RBC Capital Markets on Monday, November 2. As per Thursday, March 17, the company rating was initiated by Nomura.

According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has a market cap of $19.87 billion. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It has a 56.03 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets.

ZBH Company Profile

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Wsj.com which released: “Zimmer Biomet Cuts Forecasts” on October 31, 2016, also Reuters.com with their article: “BRIEF-Seikagaku signs exclusive distribution agreement with Zimmer Biomet …” published on November 08, 2016, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on November 01, 2016. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Businesswire.com and their article: “SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Zimmer …” published on November 02, 2016 as well as Businesswire.com‘s news article titled: “INVESTOR ALERT: Investigation of Zimmer Biomet Holdings, Inc. Announced by Law …” with publication date: November 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment